{"id":"NCT00790036","sponsor":"Novartis Pharmaceuticals","briefTitle":"Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07-24","primaryCompletion":"2016-06-15","completion":"2016-06-15","firstPosted":"2008-11-13","resultsPosted":"2017-07-12","lastUpdate":"2017-07-12"},"enrollment":742,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Diffuse Large B-cell Lymphoma"],"interventions":[{"type":"DRUG","name":"Everolimus","otherNames":["RAD001"]},{"type":"DRUG","name":"Everolimus Placebo","otherNames":[]}],"arms":[{"label":"Everolimus","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy","primaryOutcome":{"measure":"Disease-free Survival (DFS)","timeFrame":"From date of randomization to the date of event defined as the first documented recurrence of the disease, or death due to any cause and up to 6 years","effectByArm":[{"arm":"RAD001 (Everolimus)1","deltaMin":77.8,"sd":null},{"arm":"Placebo","deltaMin":77,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.276"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":202,"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","China","Colombia","Czechia","Egypt","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Lebanon","Mexico","New Zealand","Norway","Peru","Poland","Russia","Saudi Arabia","Singapore","Slovakia","South Korea","Spain","Switzerland","Thailand","Turkey (TÃ¼rkiye)","Venezuela"]},"refs":{"pmids":["29253068"],"seeAlso":["http://www.novartisclinicaltrials.com/webapp/etrials/searchTrial.do?t=i&trialID=755&keywords=crad001n2301"]},"adverseEventsSummary":{"seriousAny":{"events":105,"n":368},"commonTop":["Stomatitis","Diarrhoea","Neutropenia","Fatigue","Cough"]}}